Published in Nature on June 10, 1993
Natural History Study of Patients With Neurofibromatosis Type 2 | NCT00598351
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol (1998) 5.15
Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol (2010) 5.05
The Hippo pathway: regulators and regulations. Genes Dev (2013) 4.55
E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol (1994) 4.34
Antioncogenes and human cancer. Proc Natl Acad Sci U S A (1993) 4.09
ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol (1994) 4.09
Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol (1996) 4.06
Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol (1994) 3.68
The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev (2001) 3.65
Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol (1998) 3.39
Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell (1995) 3.36
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol (2009) 3.25
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol (2007) 2.89
Submembranous junctional plaque proteins include potential tumor suppressor molecules. J Cell Biol (1993) 2.87
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev (1998) 2.66
Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol (1997) 2.51
Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain. EMBO J (2000) 2.49
Cloning and characterization of hdlg: the human homologue of the Drosophila discs large tumor suppressor binds to protein 4.1. Proc Natl Acad Sci U S A (1994) 2.41
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell (2015) 2.31
Neurofibromatosis type 2. Lancet (2009) 2.24
Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell (2013) 2.16
Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol (1996) 2.12
Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet (2003) 2.12
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol (2009) 2.06
Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis (2009) 2.00
Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet (1997) 1.96
Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. Am J Hum Genet (2010) 1.96
The Drosophila tumor suppressors Expanded and Merlin differentially regulate cell cycle exit, apoptosis, and Wingless signaling. Dev Biol (2006) 1.85
Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet (1996) 1.83
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A (1995) 1.76
Drosophila coracle, a member of the protein 4.1 superfamily, has essential structural functions in the septate junctions and developmental functions in embryonic and adult epithelial cells. Mol Biol Cell (1998) 1.71
Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet (1996) 1.70
Structural basis of adhesion-molecule recognition by ERM proteins revealed by the crystal structure of the radixin-ICAM-2 complex. EMBO J (2003) 1.70
The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev Cell (2010) 1.67
Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain. J Mol Biol (2006) 1.66
Ezrin NH2-terminal domain inhibits the cell extension activity of the COOH-terminal domain. J Cell Biol (1995) 1.63
RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol Biol Cell (1998) 1.62
Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients. Am J Hum Genet (1998) 1.61
Merlin/ERM proteins establish cortical asymmetry and centrosome position. Genes Dev (2012) 1.60
The Drosophila lethal(2)giant larvae tumor suppressor protein forms homo-oligomers and is associated with nonmuscle myosin II heavy chain. J Cell Biol (1994) 1.59
Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg (2012) 1.59
Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol (1998) 1.58
Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin. J Cell Biol (1996) 1.56
Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet (1996) 1.52
Merlin is a potent inhibitor of glioma growth. Cancer Res (2008) 1.47
Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet (1998) 1.47
Control of leaf and chloroplast development by the Arabidopsis gene pale cress. Plant Cell (1994) 1.46
Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol (2007) 1.42
Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev (1999) 1.37
Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet (2002) 1.37
Two independent domains of hDlg are sufficient for subcellular targeting: the PDZ1-2 conformational unit and an alternatively spliced domain. J Cell Biol (1996) 1.36
ERM (ezrin/radixin/moesin)-based molecular mechanism of microvillar breakdown at an early stage of apoptosis. J Cell Biol (1997) 1.35
Molecular dissection of radixin: distinct and interdependent functions of the amino- and carboxy-terminal domains. J Cell Biol (1995) 1.34
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A (2004) 1.34
A conserved functional domain of Drosophila coracle is required for localization at the septate junction and has membrane-organizing activity. J Cell Biol (1998) 1.33
Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol (1995) 1.32
Biochemical and molecular characterization of the chicken cysteine-rich protein, a developmentally regulated LIM-domain protein that is associated with the actin cytoskeleton. J Cell Biol (1994) 1.31
Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep (2012) 1.30
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol (1999) 1.26
Identification of EPI64, a TBC/rabGAP domain-containing microvillar protein that binds to the first PDZ domain of EBP50 and E3KARP. J Cell Biol (2001) 1.26
Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol (2013) 1.26
Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1). Breast Cancer Res (2006) 1.26
Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry (1997) 1.26
EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial-mesenchymal transition. J Cell Biol (2008) 1.24
Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Mol Med (1998) 1.24
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24
Neurofibromatosis type 2. J Med Genet (2000) 1.22
Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci (2010) 1.21
The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A (2007) 1.17
Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet (1994) 1.17
Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol (2000) 1.16
A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet (1994) 1.15
The multiple functions of TRBP, at the hub of cell responses to viruses, stress, and cancer. Microbiol Mol Biol Rev (2012) 1.14
Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells. Breast Cancer Res (2008) 1.14
Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry (2004) 1.13
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One (2012) 1.13
Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet (1994) 1.13
Three determinants in ezrin are responsible for cell extension activity. Mol Biol Cell (1997) 1.12
Drosophila cancer models. Dev Dyn (2011) 1.10
Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway. Cell Res (2015) 1.09
The Angiomotins--from discovery to function. FEBS Lett (2014) 1.07
Phosphorylation and activity of the tumor suppressor Merlin and the ERM protein Moesin are coordinately regulated by the Slik kinase. J Cell Biol (2006) 1.07
Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol (2001) 1.07
Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet (2004) 1.05
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol (2010) 1.04
The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol (2002) 1.04
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics (2009) 1.03
Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett (2014) 1.03
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol (2011) 1.02
Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol (1997) 1.02
The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol (2008) 1.01
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol (2008) 1.01
Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol (2005) 1.00
Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol (2010) 1.00
Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. J Clin Pathol (2004) 1.00
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med (1994) 4.65
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet (2005) 3.77
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci (1998) 3.24
Cloning and characterization of hOGG1, a human homolog of the OGG1 gene of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1997) 3.09
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A (1993) 3.07
Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J (1993) 2.91
EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet (1993) 2.72
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology (2010) 2.53
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology (2007) 2.52
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol (2001) 2.39
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology (2010) 2.36
Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer (1992) 2.31
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet (1994) 2.28
Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol (2001) 2.24
Molecular cloning and analysis of cDNA encoding a plant tryptophan decarboxylase: comparison with animal dopa decarboxylases. Proc Natl Acad Sci U S A (1989) 2.22
DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol (1994) 2.18
Dynamics of proteasome distribution in living cells. EMBO J (1997) 2.18
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (2005) 2.09
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol (2004) 1.97
Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet (1999) 1.96
Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli. Eur J Biochem (1986) 1.89
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol (2010) 1.85
Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Mol Psychiatry (2010) 1.69
Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res (2000) 1.63
Supratentorial low-grade gliomas in older patients. Neurology (2009) 1.55
Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology (2009) 1.48
Registered Replication Report: Schooler and Engstler-Schooler (1990). Perspect Psychol Sci (2014) 1.48
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol (2001) 1.47
Cytokines and other mediators in rheumatoid arthritis. Springer Semin Immunopathol (1984) 1.45
[Benign intracranial hypertension and minocycline]. Rev Neurol (Paris) (1988) 1.42
A human homolog of the S. cerevisiae HIR1 and HIR2 transcriptional repressors cloned from the DiGeorge syndrome critical region. Hum Mol Genet (1995) 1.39
Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer (1995) 1.35
Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol (2001) 1.34
Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci (1997) 1.33
Initial chemotherapy in gliomatosis cerebri. Neurology (2004) 1.33
Limited effects of recombinant human and murine interleukin 1 and tumour necrosis factor on production of acute phase proteins by cultured rat hepatocytes. Biochem Int (1987) 1.30
Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J (2001) 1.29
Interstitial 22q11 microdeletion excluding the ADU breakpoint in a patient with DiGeorge syndrome. Hum Mol Genet (1995) 1.27
Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor. J Biol Chem (1991) 1.24
Complete deficiency of glycophorin A in red blood cells from mice with targeted inactivation of the band 3 (AE1) gene. Blood (1998) 1.23
Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost (1988) 1.21
Cloning of a balanced translocation breakpoint in the DiGeorge syndrome critical region and isolation of a novel potential adhesion receptor gene in its vicinity. Hum Mol Genet (1995) 1.20
The neurofibromatosis type 2 gene is inactivated in schwannomas. Hum Mol Genet (1994) 1.19
OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet (2001) 1.19
Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics (1993) 1.18
EGFR tyrosine kinase domain mutations in human gliomas. Neurology (2005) 1.18
Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet (1995) 1.17
Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry (2001) 1.16
Thyroid hormone alters the DNA binding properties of chicken thyroid hormone receptors alpha and beta. Nucleic Acids Res (1992) 1.14
Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology (2004) 1.14
The gene responsible for a severe form of peripheral neuropathy and agenesis of the corpus callosum maps to chromosome 15q. Am J Hum Genet (1996) 1.09
Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer (1999) 1.09
Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer (1995) 1.07
Structural Organization of the WD repeat protein-encoding gene HIRA in the DiGeorge syndrome critical region of human chromosome 22. Genome Res (1996) 1.03
Physical mapping by FISH of the DiGeorge critical region (DGCR): involvement of the region in familial cases. Am J Hum Genet (1993) 1.02
New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients. J Infect Dis (2000) 1.02
Mapping of human gamma-glutamyl transpeptidase genes on chromosome 22 and other human autosomes. Genomics (1993) 1.01
Dinucleotide repeat polymorphism at the D22S268 locus. Hum Mol Genet (1993) 1.00
Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. Genes Chromosomes Cancer (1992) 1.00
Familial non-syndromic conotruncal defects are not associated with a 22q11 microdeletion. Hum Genet (1996) 0.98
Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice. Br J Cancer (2003) 0.97
Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. Br J Cancer (2013) 0.96
Intravascular malignant lymphomatosis. Neuroradiology (2002) 0.95
The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet (1995) 0.95
[Neurofibromatosis 1: recommendations for management]. Arch Pediatr (2002) 0.94
Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology (2001) 0.94
Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathol Appl Neurobiol (2009) 0.93
Analysis of mutations in the SCH gene in schwannomas. Genes Chromosomes Cancer (1994) 0.93
Organization and expression of the lambda-like genes that contribute to the mu-psi light chain complex in human pre-B cells. Int Immunol (1991) 0.90
Varicella-zoster virus DNA in CSF and arteries in delayed contralateral hemiplegia: evidence for viral invasion of cerebral arteries. Neurology (1996) 0.89
OLIG-1 and 2 gene expression and oligodendroglial tumours. Neuropathol Appl Neurobiol (2002) 0.88
Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. Cancer Genet Cytogenet (1994) 0.88
p53 mutations in human tumors with chimeric EWS/FLI-1 genes. Int J Cancer (1994) 0.88
Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer (2004) 0.88